In today’s session Retrophin Inc (RTRX) registered an unusually high (500) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the March, 2017 call, expecting serious RTRX increase. With 500 contracts traded and 15154 open interest for the Mar, 17 contract, it seems this is a quite bullish bet. The option with symbol: RTRX170317C00022500 closed last at: $3.3 or 3.1% up. About 8,175 shares traded hands. Retrophin Inc (NASDAQ:RTRX) has risen 37.67% since April 22, 2016 and is uptrending. It has outperformed by 32.26% the S&P500.
Analysts await Retrophin Inc (NASDAQ:RTRX) to report earnings on February, 23. They expect $-0.21 earnings per share, down 400.00% or $0.28 from last year’s $0.07 per share. After $-0.25 actual earnings per share reported by Retrophin Inc for the previous quarter, Wall Street now forecasts -16.00% EPS growth.
Retrophin Inc (NASDAQ:RTRX) Ratings Coverage
Out of 3 analysts covering Retrophin (NASDAQ:RTRX), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $44 is the highest target while $25 is the lowest. The $33 average target is 53.20% above today’s ($21.54) stock price. Retrophin has been the topic of 4 analyst reports since August 12, 2015 according to StockzIntelligence Inc. The stock has “Buy” rating given by Zacks on Wednesday, August 12. JMP Securities initiated Retrophin Inc (NASDAQ:RTRX) rating on Monday, November 2. JMP Securities has “Mkt Outperform” rating and $30 price target. BMO Capital Markets initiated it with “Outperform” rating and $25 target price in Tuesday, April 12 report.
According to Zacks Investment Research, “Retrophin is a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are currently no viable options for patients. The Company’s approved products include ChenodalÂ®, Cholbam, and ThiolaÂ®, and its pipeline includes compounds for several catastrophic diseases, including focal segmental glomerulosclerosis, pantothenate kinase-associated neurodegeneration, infantile spasms, nephrotic syndrome and others. Retrophin, Inc. is based in San Diego.”
Insitutional Activity: The institutional sentiment increased to 1.63 in Q2 2016. Its up 0.33, from 1.3 in 2016Q1. The ratio is positive, as 15 funds sold all Retrophin Inc shares owned while 29 reduced positions. 12 funds bought stakes while 45 increased positions. They now own 38.66 million shares or 4.59% more from 36.97 million shares in 2016Q1.
Marshall Wace Limited Liability Partnership last reported 90,194 shares in the company. Zurcher Kantonalbank (Zurich Cantonalbank) has 0% invested in the company for 1,633 shares. Rhumbline Advisers last reported 44,236 shares in the company. The Connecticut-based Tudor Investment Corporation Et Al has invested 0.01% in Retrophin Inc (NASDAQ:RTRX). The New Jersey-based Round Table has invested 0.6% in Retrophin Inc (NASDAQ:RTRX). Blackrock Group Incorporated last reported 0% of its portfolio in the stock. Wall Street Assoc has invested 1.42% of its portfolio in Retrophin Inc (NASDAQ:RTRX). Rock Springs Capital Limited Partnership last reported 0.69% of its portfolio in the stock. Swiss Bancorp accumulated 56,200 shares or 0% of the stock. Cornerstone Cap Mngmt Lc, a New York-based fund reported 7,900 shares. The New York-based Millennium Management Ltd Liability Corporation has invested 0.03% in Retrophin Inc (NASDAQ:RTRX). Voya Management Limited Company has 16,014 shares for 0% of their US portfolio. Blackrock Advsrs accumulated 65,252 shares or 0% of the stock. Blackrock Japan Ltd, a Japan-based fund reported 443 shares. Ny State Common Retirement Fund last reported 0% of its portfolio in the stock.
Insider Transactions: Since June 1, 2016, the stock had 0 buys, and 3 sales for $470,503 net activity. Shih Alvin had sold 8,750 shares worth $142,059 on Thursday, September 1. ASELAGE STEVE sold $173,160 worth of stock or 8,200 shares.
Retrophin, Inc. is a biopharmaceutical firm focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The company has a market cap of $826.99 million. It sells three products, including Chenodal , Cholbam (cholic acid) and Thiola (tiopronin). It currently has negative earnings. The Company’s Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age.
RTRX Company Profile
Retrophin, Inc. (Retrophin), incorporated on February 7, 2008, is a biopharmaceutical company. The Firm is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Firm sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). The Company’s Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has also been care for cerebrotendinous xanthomatosis (CTX) patients. The Company’s Cholbam is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders. The Company’s Thiola is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.
More recent Retrophin Inc (NASDAQ:RTRX) news were published by: Fool.com which released: “Why Shares of Retrophin Inc Are Soaring Today” on September 07, 2016. Also Fool.com published the news titled: “Why Retrophin Inc was Down Today” on February 10, 2016. Reuters.com‘s news article titled: “Retrophin to pay $3 million in US lawsuit over Shkreli’s tenure” with publication date: February 03, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.